ATE496901T1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents
Cannabinoidderivate, verfahren zu deren herstellung und deren verwendungInfo
- Publication number
- ATE496901T1 ATE496901T1 AT04752828T AT04752828T ATE496901T1 AT E496901 T1 ATE496901 T1 AT E496901T1 AT 04752828 T AT04752828 T AT 04752828T AT 04752828 T AT04752828 T AT 04752828T AT E496901 T1 ATE496901 T1 AT E496901T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- tetrahydrocannabinol
- delta
- cannabinoid derivatives
- cannabinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47231603P | 2003-05-20 | 2003-05-20 | |
PCT/US2004/015885 WO2004113320A1 (en) | 2003-05-20 | 2004-05-20 | Cannabinoid derivatives, methods of making, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE496901T1 true ATE496901T1 (de) | 2011-02-15 |
Family
ID=33539041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04752828T ATE496901T1 (de) | 2003-05-20 | 2004-05-20 | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung |
Country Status (10)
Country | Link |
---|---|
US (2) | US7169942B2 (de) |
EP (1) | EP1633733B1 (de) |
JP (1) | JP2007501279A (de) |
CN (1) | CN1809552A (de) |
AT (1) | ATE496901T1 (de) |
AU (1) | AU2004249669B2 (de) |
CA (1) | CA2526103A1 (de) |
DE (1) | DE602004031221D1 (de) |
DK (1) | DK1633733T3 (de) |
WO (1) | WO2004113320A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093052A1 (en) * | 2004-03-26 | 2005-10-06 | Fuji Photo Film Co., Ltd. | Method for selectively separating and purifying rna and method for separating and purifying nucleic acid |
USRE46558E1 (en) | 2005-04-28 | 2017-09-26 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
WO2007041167A2 (en) * | 2005-09-29 | 2007-04-12 | Amr Technology, Inc. | Process for production of delta-9-tetrahydrocannabinol |
DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
AU2007219981B2 (en) * | 2006-02-28 | 2013-11-07 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
WO2008109027A2 (en) | 2007-03-02 | 2008-09-12 | University Of Tennessee Research Foundation, The | Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
WO2009120799A2 (en) * | 2008-03-25 | 2009-10-01 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
US8541431B2 (en) * | 2008-05-19 | 2013-09-24 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
JP2011520973A (ja) * | 2008-05-19 | 2011-07-21 | ユニヴァーシティ オブ テネシー リサーチ ファウンデーション,ザ | ピリジンの非古典的カンナビノイド化合物及び関連する使用方法 |
US8349876B2 (en) * | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
US8476439B2 (en) | 2008-05-19 | 2013-07-02 | The University Of Tennessee Research Foundation | Pyridine classical cannabinoid compounds and related methods of use |
CA2724733A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine classical cannabinoid compounds and related methods of use |
US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
CA2724697A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyridine classical cannabinoid compounds and related methods of use |
WO2010013240A1 (en) | 2008-07-31 | 2010-02-04 | Dekel Pharmaceuticals Ltd. | Compositions and methods for treating inflammatory disorders |
WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
CN103110582A (zh) * | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
WO2015200049A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US20170008869A1 (en) * | 2015-07-10 | 2017-01-12 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Formulations of dilutable cannabinoids and processes for their preparation |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
US20180169061A1 (en) * | 2016-12-15 | 2018-06-21 | Ascent Pharmaceuticals, Inc. | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations |
KR102652605B1 (ko) | 2017-08-27 | 2024-03-28 | 로드스 테크놀로지즈 | 안과 질환 치료를 위한 약학제적 조성물 |
EP3745884A1 (de) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hanfpulver |
WO2020041326A1 (en) * | 2018-08-20 | 2020-02-27 | Berkowitz Barry A | Applications of known and novel cannabinoids |
US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
CN110269839A (zh) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 |
CN114901071A (zh) | 2019-11-08 | 2022-08-12 | 维拉生物科技有限公司 | 外周作用的含有大麻二酚(cbd)的组合物及其用于增强女性性功能或治疗女性性障碍的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941782A (en) * | 1972-04-27 | 1976-03-02 | Sharps Associates | Heterocyclic esters of benzopyrans |
US3915996A (en) | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
US3901926A (en) * | 1973-04-02 | 1975-08-26 | Abbott Lab | Alkylphenyl benzopyrans |
DE4100441A1 (de) * | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol |
US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
EP0971588B1 (de) | 1997-01-21 | 2004-03-17 | Smithkline Beecham Corporation | Neue cannabinoidrezeptor-modulatoren |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
US5939429A (en) | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
ATE247097T1 (de) * | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
US6563009B1 (en) | 1999-07-12 | 2003-05-13 | Virginia Commonwealth University | Vasodilator cannabinoid analogs |
FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
KR20030008153A (ko) * | 2000-06-22 | 2003-01-24 | 파모스 코포레이션 | 신규 비-향정신성 카나비노이드 |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
KR20050044417A (ko) | 2001-11-14 | 2005-05-12 | 쉐링 코포레이션 | 카나비노이드 수용체 리간드 |
PE20040574A1 (es) | 2002-06-19 | 2004-09-08 | Schering Corp | Agonistas de los receptores cannabinoides |
US20040077650A1 (en) | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2004
- 2004-05-20 AT AT04752828T patent/ATE496901T1/de not_active IP Right Cessation
- 2004-05-20 DK DK04752828.6T patent/DK1633733T3/da active
- 2004-05-20 JP JP2006533257A patent/JP2007501279A/ja active Pending
- 2004-05-20 DE DE602004031221T patent/DE602004031221D1/de active Active
- 2004-05-20 AU AU2004249669A patent/AU2004249669B2/en not_active Ceased
- 2004-05-20 EP EP04752828A patent/EP1633733B1/de not_active Not-in-force
- 2004-05-20 WO PCT/US2004/015885 patent/WO2004113320A1/en active Application Filing
- 2004-05-20 US US10/850,588 patent/US7169942B2/en not_active Expired - Fee Related
- 2004-05-20 CA CA002526103A patent/CA2526103A1/en not_active Abandoned
- 2004-05-20 CN CNA2004800174008A patent/CN1809552A/zh active Pending
-
2007
- 2007-01-26 US US11/698,665 patent/US20070167514A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1633733A1 (de) | 2006-03-15 |
CN1809552A (zh) | 2006-07-26 |
US20070167514A1 (en) | 2007-07-19 |
JP2007501279A (ja) | 2007-01-25 |
EP1633733B1 (de) | 2011-01-26 |
WO2004113320A1 (en) | 2004-12-29 |
DE602004031221D1 (de) | 2011-03-10 |
AU2004249669B2 (en) | 2008-05-22 |
CA2526103A1 (en) | 2004-12-29 |
AU2004249669A1 (en) | 2004-12-29 |
EP1633733A4 (de) | 2007-02-28 |
US20040242593A1 (en) | 2004-12-02 |
DK1633733T3 (da) | 2011-05-16 |
US7169942B2 (en) | 2007-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE496901T1 (de) | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung | |
NO20010446L (no) | Substituert anilidforbindelser og metoder | |
DE69728585D1 (de) | Mittel gegen Juckreiz | |
ATE338565T1 (de) | Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm) | |
ATE365165T1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
ATE328874T1 (de) | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren | |
BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
DE60207514D1 (de) | Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten | |
DE69422191D1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
EP1017713A4 (de) | ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN | |
BR9707136A (pt) | Derivados morfinóides condesados em heterociclo (ii) | |
BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
ATE272631T1 (de) | Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung | |
BR0015962A (pt) | Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias | |
DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
DK1019426T3 (da) | Hidtil ukendte A1-adenosinreceptoragonister og -antagonister | |
ATE239823T1 (de) | Verffahren und vorrichtung zur steuerung der papiereigenschaften | |
DE60103384D1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
HUP0100621A2 (hu) | Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények | |
ATE227760T1 (de) | Mit nanopartikeln modifizierte bindemittel für überzugsmittel und deren verwendung | |
ATE269340T1 (de) | Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
AU5614198A (en) | Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors | |
BRPI0409730A (pt) | tratamento da incontinência | |
BR0307903A (pt) | derivados de arilsulfona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |